Receiving a HER2-positive breast cancer diagnosis can be life-changing. Some of your first questions may be how a HER2-positive diagnosis will affect your prognosis (outlook) and what the HER2-positive breast cancer survival rates look like.

Human epidermal growth factor receptor 2, or HER2, is a protein that helps normal cells grow. Some breast cancers make extra copies of the HER2 gene or high levels of HER2 protein, which can cause breast cancer cells to grow and multiply rapidly. Over the past 30 years, new treatments have dramatically improved the outlook for people with HER2-positive breast cancer.

Read on to learn more about HER2-positive breast cancer prognosis and survival rates.

🗳️ What’s most helpful for you when managing stress or anxiety about your prognosis?

Connecting with loved ones

Finding comfort in faith and spiritual community

Practicing meditation and mindfulness

Participating in hobbies

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

How Does HER2 Affect Survival Rates?

HER2-positive breast cancers tend to grow faster than HER2-negative breast cancers. In the past, HER2-positive breast cancer was associated with a poorer prognosis than some other types of breast cancer.

However, newer cancer treatments targeting HER2 proteins have improved outcomes and survival rates. Because it takes time to collect and analyze scientific data, current survival statistics may not fully reflect the benefits of the newest treatments.

HER2-positive breast cancer responds well to modern treatments. Survival rates have improved significantly but vary based on several factors, including the stage at diagnosis.

Sometimes, breast cancer can recur (come back) after initial treatment. Targeted treatments for HER2-positive breast cancer help reduce the risk of recurrence.

Understanding HER2-Positive Breast Cancer Survival Rates

When doctors describe survival rates for cancer, they often refer to the five-year survival rate. This statistic estimates the percentage of people with a type of cancer who are still alive five years after their diagnosis.

For example, if a specific cancer has an 80 percent five-year survival rate, it means that 80 out of 100 people with that cancer were alive five years after their diagnosis.

Doctors may also talk about relative survival rates. These rates compare people with cancer with similar people of the same age who don’t have that cancer. An 80 percent five-year relative survival rate means that people with the cancer are 80 percent as likely to be alive five years after diagnosis as those without it.

Factors Influencing Prognosis of HER2-Positive Breast Cancer

HER2-positive breast cancer has different survival rates than HER2-negative breast cancer. Breast cancer survival rates depend on many factors, including:

• Stage of cancer, including tumor size and whether axillary (nearby) lymph nodes are involved
• Any metastasis (whether the cancer has spread to distant parts of the body)
• Breast cancer subtypes
• Treatment approach
• Individual factors, such as age, genetics, and overall health

It’s important to remember that survival rates are estimates based on large groups of people and can’t predict exactly what will happen for you. Your prognosis depends on your individual circumstances and risk factors.

Stage and Extent of Cancer Spread

Many factors can affect HER2 breast cancer prognosis, but researchers consider stage at diagnosis to be the most powerful factor in determining HER2 breast cancer survival rates. Stage describes the size of the cancer and how far it has spread.

Healthcare providers use the TNM system to help determine breast cancer stage. TNM stands for “tumor size, node involvement, and metastasis.” In general, breast cancer diagnosed at an earlier stage has a better prognosis than cancer diagnosed at a later stage.

For survival statistics, the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program groups breast cancer by how far it has spread:

• Localized — Has not spread outside the breast
• Regional — Has spread outside the breast to nearby structures or lymph nodes
• Distant — Has spread to distant parts of the body, also called metastatic breast cancer

Hormone Receptor Status

Breast cancer can also be positive or negative for proteins called hormone receptors (HRs). HR-positive breast cancer has receptors for hormones such as estrogen or progesterone. Hormone receptor status helps doctors classify breast cancer and choose treatments.

Survival rates vary based on hormone receptor status. For HER2-positive female breast cancer, the most recent available SEER data from 2016 through 2022 shows the following five-year relative survival rates:

Localized Breast Cancer Survival Rates

• 99.5 percent for HER2-positive, HR-positive breast cancer
• 97.8 percent for HER2-positive, HR-negative breast cancer

Regional Breast Cancer Survival Rates

• 91.5 percent for HER2-positive, HR-positive breast cancer
• 86.4 percent for HER2-positive, HR-negative breast cancer

Distant Breast Cancer Survival Rates

• 48.7 percent for HER2-positive, HR-positive breast cancer
• 43.1 percent for HER2-positive, HR-negative breast cancer

Survival statistics are based on people diagnosed and treated several years ago, so they may not reflect the benefits of the newest treatments. Breast cancer survival rates have generally improved over time, and outcomes may continue to improve as treatments advance.

Treatments for HER2-Positive Breast Cancer

Many treatment options are available for HER2-positive breast cancer. Because it has high levels of HER2 proteins, HER2-positive breast cancer can be treated with drugs that specifically target HER2.

HER2-targeted medications work in different ways to block the protein or the signals that help cancer cells grow and multiply. Depending on the drug and stage of cancer, HER2-targeted therapies may be used for early-stage or advanced breast cancer.

Many HER2-specific treatments are monoclonal antibodies that attach to HER2 on cancer cells. Some can also help the immune system recognize and destroy cancer cells.

Monoclonal Antibodies

Monoclonal antibodies are a type of targeted therapy used to treat HER2-positive breast cancer. These laboratory-made antibodies attach to the HER2 protein and can block signals that help cancer cells grow. Monoclonal antibody therapies used for HER2-positive breast cancer include:

• Margetuximab-cmkb (Margenza), given intravenously
• Pertuzumab (Perjeta), given intravenously
• Pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo), given as an injection under the skin
• Trastuzumab (Herceptin and its biosimilars), given intravenously or as an injection under the skin, depending on the formulation

Tyrosine Kinase Inhibitors

Some drugs block signals from enzymes called tyrosine kinases that help cancer cells grow. Tyrosine kinase inhibitor medications used for HER2-positive breast cancer include:

• Lapatinib (Tykerb)
• Neratinib (Nerlynx)
• Tucatinib (Tukysa)

Antibody-Drug Conjugates

Antibody-drug conjugates, such as ado-trastuzumab emtansine (Kadcyla) and fam-trastuzumab deruxtecan-nxki (Enhertu), are also used for HER2-positive breast cancer. These treatments combine an antibody that attaches to HER2 with a cancer-killing drug, helping deliver the drug directly to cancer cells.

The U.S. Food and Drug Administration (FDA) expanded approvals for fam-trastuzumab deruxtecan-nxki in 2025 and 2026. In May 2026, the FDA approved Enhertu for certain people with HER2-positive early-stage breast cancer.

CDK4/6 Inhibitors

Cancer can sometimes become resistant to some treatments, and researchers are developing targeted therapies to overcome resistance. CDK4/6 inhibitors block proteins that help cancer cells divide.

In June 2026, the FDA approved palbociclib (Ibrance) with other therapies for certain HR-positive/HER2-positive locally advanced or metastatic disease.

Many targeted therapies for HER2-positive breast cancer are given with other treatments, such as chemotherapy, radiation therapy, or surgery. Depending on the treatment and stage of breast cancer, targeted therapies may be given before or after surgery or used to treat advanced cancer.

New Research on HER2-Positive Breast Cancer Treatments

Oncology research aimed at improving treatments for HER2-positive breast cancer continues to grow. For example, drug companies are studying new antibody-drug conjugates, tyrosine kinase inhibitors, and combinations of existing treatments.

Hundreds of clinical trials focus on HER2-positive breast cancer. This cancer research is studying new treatments and combinations to learn which approaches work best for different groups of people. The goal is to keep improving outcomes for people living with HER2-positive breast cancer.